$ATRA
Atara Biotherapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024125389 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $40.19M
YoY Change 1779.79%
Cost Of Revenue $7.602M
YoY Change 190.15%
Gross Profit $32.59M
YoY Change -6889.17%
Gross Profit Margin 81.08%
Selling, General & Admin $10.42M
YoY Change -14.93%
% of Gross Profit 31.98%
Research & Development $43.92M
YoY Change -22.79%
% of Gross Profit 134.79%
Depreciation & Amortization $600.0K
YoY Change -33.33%
% of Gross Profit 1.84%
Operating Expenses $43.92M
YoY Change -22.79%
Operating Profit -$21.76M
YoY Change -68.75%
Interest Expense $1.183M
YoY Change -15.2%
% of Operating Profit
Other Income/Expense, Net $555.0K
YoY Change -2155.56%
Pretax Income -$21.93M
YoY Change -68.59%
Income Tax -$17.00K
% Of Pretax Income
Net Earnings -$21.91M
YoY Change -68.61%
Net Earnings / Revenue -54.51%
Basic Earnings Per Share -$2.93
Diluted Earnings Per Share -$2.93
COMMON SHARES
Basic Shares Outstanding 5.760M 4.915M
Diluted Shares Outstanding 7.466M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.19M
YoY Change -34.39%
Cash & Equivalents $46.45M
Short-Term Investments $20.74M
Other Short-Term Assets $9.205M
YoY Change -1.95%
Inventory $13.98M
Prepaid Expenses
Receivables $1.335M
Other Receivables $0.00
Total Short-Term Assets $91.86M
YoY Change -22.61%
LONG-TERM ASSETS
Property, Plant & Equipment $1.661M
YoY Change -64.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.357M
YoY Change -46.62%
Total Long-Term Assets $50.85M
YoY Change -27.45%
TOTAL ASSETS
Total Short-Term Assets $91.86M
Total Long-Term Assets $50.85M
Total Assets $142.7M
YoY Change -24.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.146M
YoY Change -67.04%
Accrued Expenses $8.059M
YoY Change -2.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.006M
YoY Change 11.78%
Total Short-Term Liabilities $156.0M
YoY Change 97.22%
LONG-TERM LIABILITIES
Long-Term Debt $37.58M
YoY Change
Other Long-Term Liabilities $3.969M
YoY Change -18.13%
Total Long-Term Liabilities $3.969M
YoY Change -18.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $156.0M
Total Long-Term Liabilities $3.969M
Total Liabilities $233.2M
YoY Change -2.66%
SHAREHOLDERS EQUITY
Retained Earnings -$2.042B
YoY Change 6.98%
Common Stock $1.951B
YoY Change 5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$90.54M
YoY Change
Total Liabilities & Shareholders Equity $142.7M
YoY Change -24.41%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$21.91M
YoY Change -68.61%
Depreciation, Depletion And Amortization $600.0K
YoY Change -33.33%
Cash From Operating Activities -$3.989M
YoY Change -92.23%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$16.67M
YoY Change -123.56%
Cash From Investing Activities -$16.67M
YoY Change -123.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 35.79M
YoY Change -17144.29%
NET CHANGE
Cash From Operating Activities -3.989M
Cash From Investing Activities -16.67M
Cash From Financing Activities 35.79M
Net Change In Cash 15.14M
YoY Change -19.86%
FREE CASH FLOW
Cash From Operating Activities -$3.989M
Capital Expenditures $0.00
Free Cash Flow -$3.989M
YoY Change -92.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001604464
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36548
dei Entity Registrant Name
EntityRegistrantName
ATARA BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0920988
dei Entity Address Address Line1
EntityAddressAddressLine1
2380 Conejo Spectrum Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Thousand Oaks
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91320
dei City Area Code
CityAreaCode
805
dei Local Phone Number
LocalPhoneNumber
623-4211
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ATRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5759750
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46453000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25841000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
20736000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
25884000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1335000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34108000
CY2024Q3 us-gaap Inventory Net
InventoryNet
13980000
CY2023Q4 us-gaap Inventory Net
InventoryNet
9706000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9205000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6184000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
91855000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
101869000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1661000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3856000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45833000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54935000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3357000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4844000
CY2024Q3 us-gaap Assets
Assets
142706000
CY2023Q4 us-gaap Assets
Assets
165504000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2146000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3684000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7768000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11519000
CY2024Q3 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6077000
CY2023Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
17364000
CY2024Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
116344000
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
77833000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
23644000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31826000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
155979000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
142226000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
470000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37562000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35243000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45693000
CY2024Q3 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
37584000
CY2023Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
34623000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3969000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4631000
CY2024Q3 us-gaap Liabilities
Liabilities
233245000
CY2023Q4 us-gaap Liabilities
Liabilities
264735000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5740000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5740000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4258000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4258000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1951298000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1870123000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-204000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2041860000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1969150000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-90539000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99231000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142706000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165504000
CY2024Q3 atra Commercialization Revenue
CommercializationRevenue
40190000
CY2023Q3 atra Commercialization Revenue
CommercializationRevenue
2020000
atra Commercialization Revenue
CommercializationRevenue
96187000
atra Commercialization Revenue
CommercializationRevenue
3697000
CY2024Q3 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
0
CY2023Q3 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
118000
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
0
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
624000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
40190000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2138000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
96187000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4321000
CY2024Q3 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
7602000
CY2023Q3 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
2615000
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
14214000
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
5726000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43924000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56888000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122762000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175185000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10421000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12247000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30446000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39454000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
61947000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
71750000
us-gaap Costs And Expenses
CostsAndExpenses
167422000
us-gaap Costs And Expenses
CostsAndExpenses
220365000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21757000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-69612000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71235000
us-gaap Operating Income Loss
OperatingIncomeLoss
-216044000
CY2024Q3 us-gaap Interest Income Operating
InterestIncomeOperating
459000
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
1218000
us-gaap Interest Income Operating
InterestIncomeOperating
1513000
us-gaap Interest Income Operating
InterestIncomeOperating
4715000
CY2024Q3 us-gaap Interest Expense
InterestExpense
1183000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1395000
us-gaap Interest Expense
InterestExpense
3598000
us-gaap Interest Expense
InterestExpense
4109000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
555000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
617000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-234000
CY2024Q3 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
-169000
CY2023Q3 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
-204000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
-1468000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
372000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21926000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69816000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72703000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-215672000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-17000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-21909000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-69797000
us-gaap Net Income Loss
NetIncomeLoss
-72710000
us-gaap Net Income Loss
NetIncomeLoss
-215676000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
36000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
362000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
226000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1496000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21873000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69435000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72484000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-214180000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.93
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.93
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.4
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-51.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-51.27
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7466000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7466000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4256000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4256000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6414000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6414000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4207000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4207000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99231000
CY2024Q1 atra Issuance Of Pre Funded Warrants Net Of Offering Costs
IssuanceOfPreFundedWarrantsNetOfOfferingCosts
177000
CY2024Q1 atra Issuance Of Pre Funded Warrants Registered Direct Offering Value
IssuanceOfPreFundedWarrantsRegisteredDirectOfferingValue
14823000
CY2024Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
9312000
CY2024Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
6000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8397000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31752000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
149000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-98308000
CY2024Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1000
CY2024Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
113000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6336000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-19049000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-110868000
CY2024Q3 atra Issuance Of Pre Funded Warrants Net Of Offering Costs
IssuanceOfPreFundedWarrantsNetOfOfferingCosts
220000
CY2024Q3 atra Issuance Of Pre Funded Warrants Registered Direct Offering Value
IssuanceOfPreFundedWarrantsRegisteredDirectOfferingValue
35780000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6422000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-21909000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
36000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-90539000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
590000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
93000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11764000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-74771000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
830000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64960000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1000
CY2023Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
747000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12552000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-71108000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7454000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11143000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-69797000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
362000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-50838000
us-gaap Profit Loss
ProfitLoss
-72710000
us-gaap Profit Loss
ProfitLoss
-215676000
us-gaap Share Based Compensation
ShareBasedCompensation
21155000
us-gaap Share Based Compensation
ShareBasedCompensation
35459000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3951000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3624000
us-gaap Accretion Expense
AccretionExpense
3180000
us-gaap Accretion Expense
AccretionExpense
3729000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
30000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1320000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
9102000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
8847000
atra Other Non Cash Items Net
OtherNonCashItemsNet
-340000
atra Other Non Cash Items Net
OtherNonCashItemsNet
148000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-32773000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-40058000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4274000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5005000
atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
3135000
atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
-920000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
254000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
119000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1537000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-319000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3751000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3229000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-11287000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-1024000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-10446000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
607000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1419000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
540000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-8062000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-9953000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
142000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44246000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142571000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19665000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
83647000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
25069000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
198723000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
156000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1179000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5248000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113922000
atra Proceeds From Sale Of Common Stock And Pre Funded Warrants In Registered Direct Offerings
ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInRegisteredDirectOfferings
50813000
atra Proceeds From Sale Of Common Stock And Pre Funded Warrants In Registered Direct Offerings
ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInRegisteredDirectOfferings
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9348000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
590000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
113000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
747000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
94000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
657000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
732000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59610000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
498000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
20612000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28151000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25987000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46599000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64937000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
atra Non Cash Investing And Financing Activities Accrued Costs Related To Direct Registered Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToDirectRegisteredOffering
210000
atra Non Cash Investing And Financing Activities Accrued Costs Related To Direct Registered Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToDirectRegisteredOffering
0
us-gaap Interest Paid Net
InterestPaidNet
497000
us-gaap Interest Paid Net
InterestPaidNet
332000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
24000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, accrued research and development expenses, stock-based compensation expense, income taxes and the liability related to the sale of future revenues. Actual results could differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
794295
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
848707
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
65798000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
65820000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
50393000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
50189000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
65798000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
65820000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
50393000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50189000
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
100000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
300000
CY2024Q3 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2023Q3 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46453000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25841000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46599000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25987000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
31400000
CY2024Q3 atra Revenue Recognition Performance Satisfied Or Partially Satisfied Prior Period
RevenueRecognitionPerformanceSatisfiedOrPartiallySatisfiedPriorPeriod
8800000
atra Revenue Recognition Performance Satisfied Or Partially Satisfied Prior Period
RevenueRecognitionPerformanceSatisfiedOrPartiallySatisfiedPriorPeriod
8800000
CY2023Q4 atra Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
35076000
us-gaap Accretion Expense
AccretionExpense
3180000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
52000
us-gaap Payments For Royalties
PaymentsForRoyalties
132000
CY2024Q3 atra Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
38176000
CY2024Q3 atra Liability Related To The Sale Of Future Revenue Current
LiabilityRelatedToTheSaleOfFutureRevenueCurrent
592000
CY2024Q3 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
37584000
CY2023Q4 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.30
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6700000
CY2024Q1 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.25
CY2024Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
5100000
CY2024Q3 atra Restructuring Liability Jan2024
RestructuringLiabilityJan2024
200000
CY2024Q3 us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
5107000
us-gaap Restructuring Charges
RestructuringCharges
45000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
4923000
us-gaap Restructuring Charges
RestructuringCharges
5107000
us-gaap Payments For Restructuring
PaymentsForRestructuring
9157000
atra Non Cash Settlements
NonCashSettlements
-666000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
207000
CY2024Q3 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2023Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2024Q3 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2024Q3 atra Minimum Commitments Expense
MinimumCommitmentsExpense
3000000
atra Minimum Commitments Expense
MinimumCommitmentsExpense
9700000
CY2023Q3 atra Minimum Commitments Expense
MinimumCommitmentsExpense
2800000
atra Minimum Commitments Expense
MinimumCommitmentsExpense
16100000
CY2024Q3 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
3200000
CY2023Q4 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
11200000
CY2024Q3 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2023Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2024Q3 atra Sub Licensing Fees
SubLicensingFees
6000000
atra Sub Licensing Fees
SubLicensingFees
6000000
CY2024Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2023Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
758900
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.25
CY2024Q3 atra Common Stock Value Remained Available To Be Sold
CommonStockValueRemainedAvailableToBeSold
88700000
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1252221
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6422000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11143000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21155000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35459000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1652000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2335000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
12328000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
7371000
CY2024Q3 us-gaap Inventory Net
InventoryNet
13980000
CY2023Q4 us-gaap Inventory Net
InventoryNet
9706000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19708000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19725000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18047000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15869000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1661000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3856000
CY2024Q3 us-gaap Depreciation
Depreciation
600000
CY2023Q3 us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
2200000
us-gaap Depreciation
Depreciation
2800000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8059000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19007000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13652000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11264000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1006000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
915000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
927000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
640000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
23644000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31826000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-125389-index-headers.html Edgar Link pending
0000950170-24-125389-index.html Edgar Link pending
0000950170-24-125389.txt Edgar Link pending
0000950170-24-125389-xbrl.zip Edgar Link pending
atra-20240930.htm Edgar Link pending
atra-20240930.xsd Edgar Link pending
atra-ex31_1.htm Edgar Link pending
atra-ex31_2.htm Edgar Link pending
atra-ex32_1.htm Edgar Link pending
atra-20240930_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable